Stifel, Morgan Stanley Bullish on Newly Public Contineum

Seeking AlphaMay 1 01:10

Contineum Therapeutics Price Target Announced at $29.00/Share by Stifel

Contineum Therapeutics Price Target Announced at $29.00/Share by Stifel

Dow JonesApr 30 17:30

Contineum Therapeutics Initiated at Overweight by Morgan Stanley

Contineum Therapeutics Initiated at Overweight by Morgan Stanley

Dow JonesApr 30 17:25

Contineum Therapeutics (CTNM.US) was first covered by Stifel, giving it a buy rating, with a target price of $29.00.

Contineum Therapeutics (CTNM.US) was first covered by Stifel, giving it a buy rating, with a target price of $29.00.

Zhitong FinanceApr 30 17:20

Morgan Stanley Initiates Coverage On Contineum Therapeutics With Overweight Rating, Announces Price Target of $25

Morgan Stanley analyst Jeffrey Hung initiates coverage on Contineum Therapeutics (NASDAQ:CTNM) with a Overweight rating and announces Price Target of $25.

BenzingaApr 30 17:15

Contineum Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 58.83% Morgan Stanley → $25 Initiates Coverage On → Overweight

BenzingaApr 30 17:13